Personal information

Keywords

lung cancer

Countries

Japan

Activities

Collapse all

Employment (7)

National Cancer Center Hospital East: Kashiwa, Chiba, JP

2020-04-01 to present | Staff Physician (Department of Thoracic Oncology)
Employment
Source: Self-asserted source
Hiroki Izumi

Tottori University Hospital: Yonago, Tottori, JP

2017-04-01 to 2020-03-31 (Division of Medical Oncology and Molecular Respirology)
Employment
Source: Self-asserted source
Hiroki Izumi

University of California, San Diego: San Diego, California, US

2017-09-17 to 2019-09-12 | Postdoctoral Fellow (Moores Cancer Center)
Employment
Source: Self-asserted source
Hiroki Izumi

Hino Hospital: Hino, Tottori, JP

2016-10-01 to 2017-03-31 | M.D. (Internal Medicine)
Employment
Source: Self-asserted source
Hiroki Izumi

Tottori Kenritsu Chuo Byoin: Tottori, Tottori, JP

2015-03-01 to 2016-09-30 | M.D. (Department of Respiratory Medicine )
Employment
Source: Self-asserted source
Hiroki Izumi

Tottori University: Yonago, Tottori, JP

2011-04-01 to 2015-02-28 | The Division of Medical Oncology and Molecular Respirology
Employment
Source: Self-asserted source
Hiroki Izumi

Matsue Sekijuji Byoin: Matsue, Shimane, JP

2009-04-01 to 2011-03-31 | Resident
Employment
Source: Self-asserted source
Hiroki Izumi

Education and qualifications (2)

Tottori University: Yonago, 36-1, Nishi-machi, JP

2011-04-01 to 2015-03-31 | Ph.D. (Graduate School of Medicine)
Education
Source: Self-asserted source
Hiroki Izumi

Tottori University: Yonago, 36-1, Nishi-machi, JP

2003-04-01 to 2009-03-31 | M.D. (Faculty of Medicine)
Education
Source: Self-asserted source
Hiroki Izumi

Funding (2)

EGFR 遺伝子変異陽性の進行非小細胞肺癌におけるEGFR 阻害薬耐性機序(C797S 耐性変異)を克服する新規治療法の確立を目指した研究

2020-04-01 to 2023-03-31 | Grant
Japan Agency for Medical Research and Development (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.9618179
GRANT_NUMBER:

20ck0106568h0001
Source: Self-asserted source
Hiroki Izumi via DimensionsWizard

Biomarker of immunotherapy using zoledronate-expanded gamma-delta T cell

2020-04-01 to 2022-03-31 | Grant
Japan Society for the Promotion of Science (Tokyo, JP)
URL: https://app.dimensions.ai/details/grant/grant.9208202
GRANT_NUMBER: 20K17215
Source: Self-asserted source
Hiroki Izumi via DimensionsWizard

Works (18)

The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.

Nature
2021-11-24 | Journal article
DOI: 10.1038/s41586-021-04135-5
PMID: 34819663
Source: Self-asserted source
Hiroki Izumi

EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1.

Communications biology
2021-11-01 | Journal article
DOI: 10.1038/s42003-021-02744-4
PMID: 34725466
PMC: PMC8560880
Source: Self-asserted source
Hiroki Izumi

Comparison of the efficiency of endobronchial ultrasound-guided transbronchial needle aspiration using a 22G needle versus 25G needle for the diagnosis of lymph node metastasis in patients with lung cancer: a prospective randomized, crossover study.

Translational lung cancer research
2021-09-01 | Journal article
DOI: 10.21037/tlcr-21-480
PMID: 34733625
PMC: PMC8512458
Source: Self-asserted source
Hiroki Izumi

Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer.

Cancer research
2021-07-09 | Journal article
DOI: 10.1158/0008-5472.can-20-2811
PMID: 34247147
Source: Self-asserted source
Hiroki Izumi

Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that <i>PTEN</i> Loss Contributes to Cetuximab Resistance in Head and Neck Cancer.

Molecular cancer therapeutics
2020-05-19 | Journal article
DOI: 10.1158/1535-7163.mct-19-1036
PMID: 32430488
PMC: PMC7357849
Source: Self-asserted source
Hiroki Izumi

Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature.

Molecular and clinical oncology
2019-09-18 | Journal article
DOI: 10.3892/mco.2019.1923
PMID: 31616560
PMC: PMC6781813
Source: Self-asserted source
Hiroki Izumi

Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)
2018-06-18 | Journal article
DOI: 10.1016/j.lungcan.2018.06.022
PMID: 30032832
Source: Self-asserted source
Hiroki Izumi

Development of fever following first administration of zoledronate as a prognostic factor in advanced non-small cell lung cancer patients with bone metastases.

Molecular and clinical oncology
2017-10-10 | Journal article
DOI: 10.3892/mco.2017.1447
PMID: 29285363
PMC: PMC5740853
Source: Self-asserted source
Hiroki Izumi

A case of lung abscess successfully treated by transbronchial drainage using a guide sheath.

Respirology case reports
2017-03-24 | Journal article
DOI: 10.1002/rcr2.228
PMID: 28361002
PMC: PMC5371385
Source: Self-asserted source
Hiroki Izumi

Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema.

Anticancer research
2017-02-01 | Journal article
DOI: 10.21873/anticanres.11375
PMID: 28179328
Source: Self-asserted source
Hiroki Izumi

A novel SLC34A2 mutation in a patient with pulmonary alveolar microlithiasis.

Human genome variation
2017-01-26 | Journal article
DOI: 10.1038/hgv.2016.47
PMID: 28144448
PMC: PMC5267164
Source: Self-asserted source
Hiroki Izumi

Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year.

Molecular and clinical oncology
2016-10-26 | Journal article
DOI: 10.3892/mco.2016.1063
PMID: 28105347
PMC: PMC5228415
Source: Self-asserted source
Hiroki Izumi

A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.

International journal of oncology
2015-02-04 | Journal article
DOI: 10.3892/ijo.2015.2875
PMID: 25651992
PMC: PMC4356493
Source: Self-asserted source
Hiroki Izumi

Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.

International journal of oncology
2015-01-07 | Journal article
DOI: 10.3892/ijo.2015.2815
PMID: 25573239
PMC: PMC4324589
Source: Self-asserted source
Hiroki Izumi

Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.

International journal of oncology
2014-01-08 | Journal article
DOI: 10.3892/ijo.2014.2249
PMID: 24399305
Source: Self-asserted source
Hiroki Izumi

Large cell neuroendocrine carcinoma arising from the left main bronchus.

Internal medicine (Tokyo, Japan)
2011-09-15 | Journal article
DOI: 10.2169/internalmedicine.50.5526
PMID: 21921385
Source: Self-asserted source
Hiroki Izumi

[A case of organizing pneumonia with a reversed halo sign following postoperative irradiation for breast cancer].

Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society
2011-05-01 | Journal article
PMID: 21688650
Source: Self-asserted source
Hiroki Izumi

Small cell lung cancer complicated by pulmonary sarcoidosis.

Internal medicine (Tokyo, Japan)
2010-09-15 | Journal article
DOI: 10.2169/internalmedicine.49.3797
PMID: 20847506
Source: Self-asserted source
Hiroki Izumi
How many people are using ORCID?